XM does not provide services to residents of the United States of America.
Z
Z

ZurichInsurance

Technical Summary

IndicatorValueTrend
IndicatorValueTrend
IndicatorValueTrend
IndicatorS3S2S1PR1R2R3

News

EU agency says cleaning process may be linked to Cathay Pacific A350 engine fire

UPDATE 1-EU agency says cleaning process may be linked to Cathay Pacific A350 engine fire Adds details PARIS, Sept 19 (Reuters) - Europe's aviation regulator on Thursday linked a recent engine fire on a Cathay Pacific 0293.HK Airbus A350 to a possible problem with the maintenance of its Rolls-Royce RR.L engines. The European Union Aviation Safety Agency (EASA) earlier this month ordered airlines to carry out visual inspection s on Rolls-Royce XWB-97 engines after the incident involving a Zurich-
A
R
Z

Hong Kong probe finds Cathay engine failure due to ruptured fuel hose

UPDATE 3-Hong Kong probe finds Cathay engine failure due to ruptured fuel hose Aviation authority found ruptured fuel hose in A350 jet Incident illustrates potential for fuel leaks -report AAIA urges Rolls-Royce to impose inspection requirements Recasts, adds Cathay response in paragraphs 9-10 Sept 19 (Reuters) - A probe by Hong Kong's aviation authority found a ruptured fuel hose caused a mid-flight fire on a Cathay Pacific 0293.HK operated Airbus AIR.PA A350 plane this month.
A
R
Z

GS initiates European insurers on policy rate easing, retail P&C, mix improvement

BUZZ-GS initiates European insurers on policy rate easing, retail P&C, mix improvement ** Goldman Sachs initiates coverage of European multi-line insurers, as it sees positive trend of diversification and downside protection multi-lines can provide ** Says key sub-sector themes are an impact of central bank policy easing, earnings volatility and re
A
A
A
A
Z

Vontobel assesses obesity drugs impact for Swiss insurers, med-tech companies

BUZZ-Vontobel assesses obesity drugs impact for Swiss insurers, med-tech companies ** Vontobel estimates the market potential for obesity drugs in the U.S. to reach a three-digit billion U.S. dollar amount and picks Swiss Re SRENH.S and Ypsomed YPSN.S as the most likely to profit from it ** Among Swiss life insurers, Swiss Re could benefit the most from a rising demand in life and health reinsurance, with a market share of about 15%, as obesity drugs improve life expectancy, it says ** Its posit
B
H
N
R
S
S
Z

Investors press Baloise to shake up business after Cevian swoop

Investors press Baloise to shake up business after Cevian swoop By Oliver Hirt and Paul Arnold ZURICH, Sept 10 (Reuters) - Swiss insurer Baloise BALN.S is under pressure to heed shareholder demands to shake up its portfolio and boost returns since activist investor Cevian Capital said it held over 9% of the company's stock, becoming its biggest stakeholder.
A
B
H
A
A
S
Z

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.